AbelZeta
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
9605 Medical Center Dr Ste 100, Rockvill...Phone Number
(240) 552-5870Website
www.abelzeta.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About AbelZeta
Since the treatment of our first oncology patient in 2009, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is to leverage multinational pharmaceutical companies to facilitate and maximize worldwide patient accessibility.Explore more
AbelZeta Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AbelZeta your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at AbelZeta
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if AbelZeta is spiking on competitors!
Earning: See what the market has to say on AbelZeta recently announced quarterly report
AbelZeta, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once AbelZeta has new funding data
Product Launch: Get notified when AbelZeta launches new products
Click to see if AbelZeta had a recent Job posting/layoffs
Check if AbelZeta has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to AbelZeta
Compare insights from companies similar to AbelZeta, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
AbelZeta
<$5M
11-50
Private
-
2009
SK
Sarah KellyDirector, Corporate Communications & Investor Relations
Company Profile Activity
Activity Insights
AbelZeta is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
AbelZeta is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about AbelZeta.
AbelZeta News & Media
AbelZeta Announces Remaining China Rights to GPC3 Armored CAR-T Therapy to be Acquired by AstraZeneca
ROCKVILLE, Md. and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, announced that AstraZeneca has agreed to...AbelZeta to Attend 44th Annual J.P. Morgan Healthcare Conference and Join Panel Discussion
ROCKVILLE, Md., Jan. 6, 2026 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, will attend the 44th Annual J.P....AbelZeta Announces Late-Breaking Poster Presentation at ACR Convergence 2025 of First-in-Human Phase I Trial of anti-CD20/BCMA Bispecific CAR-T Therapy in Patients with Refractory Autoimmune Diseases
ROCKVILLE, Md., Oct. 20, 2025 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, today announced that clinical data from...AbelZeta Announces Promising Long-Term Outcomes for C-CAR039, a Novel CD19/CD20 Bi-Specific CAR-T Therapy, in Patients with R/R B NHL at EHA 2025
MILAN, June 16, 2025 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, presented promising four-year clinical outcomes...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AbelZeta
Sign Up For FreeTo access detailed company insights
Since the treatment of our first oncology patient in 2009, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is to leverage multinational pharmaceutical companies to facilitate and maximize worldwide patient acces... Read More
